S2107 Adoptive immunotherapy i.e. development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment
Short descriptor: Adoptive immunotherapy
Look up S2107 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.
S2107 is the HCPCS Level II code for Adoptive immunotherapy i.e. development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment (2026). It belongs to Section S — Temporary National Codes (Non-Medicare). Under Medicare, its coverage status is: Not payable by Medicare. Part B pricing methodology: Not separately priced by Part B.
Classification & CMS Attributes
- Medicare Coverage
- Not payable by Medicare (code I)
- Part B Pricing
- Not separately priced by Part B (indicator 00)
- Type of Service
- Other medical items or services
- Effective Date
- 2002-04-01
- 2026 Maintenance
- No change this year
References
Cite This Page
Reference S2107 with the canonical source and edition:
S2107 — Adoptive immunotherapy i.e. development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/S2107
Canonical URL: https://icd10codingpro.com/hcpcs-codes/S2107